AIM: The objective of this study was to evaluate the blood platelet-lymphocyte ratio (PLR) for its prognostic value in patients with metastatic renal cell cancer (RCC). METHODS: We retrospectively reviewed 100 patients diagnosed with metastatic RCC previously treated with tyrosine kinase inhibitors from three centers. We assessed the prognostic value of pretreatment PLR and other clinical and laboratory parameters based on univariate and multivariate analyses. RESULTS: Median progression-free survival (PFS) was 7.3 months and median overall survival (OS) was 15.3 months. Multivariate analysis revealed that PFS is significantly affected by ECOG PS (P = 0.047), PLR (P = 0.029) and calcium level (P = 0.023). Median PFS was 13.9 versus 5.3 months in patients with PLR ≤ 210 versus PLR > 210 (log rank; P = 0.001). Median OS was 25.9 versus 10.9 months with PLR ≤ 210 versus PLR > 210 (log rank; P = 0.013). CONCLUSIONS: This study shows that increased pretreatment PLR is an independent prognostic indicator in patients with metastatic RCC who use tyrosine kinase inhibitors.
AIM: The objective of this study was to evaluate the blood platelet-lymphocyte ratio (PLR) for its prognostic value in patients with metastatic renal cell cancer (RCC). METHODS: We retrospectively reviewed 100 patients diagnosed with metastatic RCC previously treated with tyrosine kinase inhibitors from three centers. We assessed the prognostic value of pretreatment PLR and other clinical and laboratory parameters based on univariate and multivariate analyses. RESULTS: Median progression-free survival (PFS) was 7.3 months and median overall survival (OS) was 15.3 months. Multivariate analysis revealed that PFS is significantly affected by ECOG PS (P = 0.047), PLR (P = 0.029) and calcium level (P = 0.023). Median PFS was 13.9 versus 5.3 months in patients with PLR ≤ 210 versus PLR > 210 (log rank; P = 0.001). Median OS was 25.9 versus 10.9 months with PLR ≤ 210 versus PLR > 210 (log rank; P = 0.013). CONCLUSIONS: This study shows that increased pretreatment PLR is an independent prognostic indicator in patients with metastatic RCC who use tyrosine kinase inhibitors.
Authors: Oktay Halit Aktepe; Gürkan Güner; Deniz Can Güven; Taha Koray Şahin; Fadime Sinem Ardıç; Deniz Yüce; Şuayib Yalçın; Mustafa Erman Journal: Turk J Med Sci Date: 2021-04-30 Impact factor: 0.973
Authors: Tae Ju Park; Yang Hyun Cho; Ho Seok Chung; Eu Chang Hwang; Sung-Hoon Jung; Jun Eul Hwang; Woo Kyun Bae; Jin Woong Kim; Suk Hee Heo; Young Hoe Hur; Seung Il Jung; Dong Deuk Kwon Journal: Springerplus Date: 2016-10-28
Authors: Song Yue; Jiahua Zhang; Jingyang Wu; Weiping Teng; Lei Liu; Lei Chen Journal: Int J Environ Res Public Health Date: 2015-08-21 Impact factor: 3.390